CytoSorbents Corporation

CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery
Health, Medical, & Dental Supplies and Equipment

CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J., Oct. 2, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader using its CytoSorb® blood purification technology to treat life-threatening medical and surgical conditions around the world, announces positive surgical outcomes in a recent publication entitled, "CytoSorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of...

Read More »
Company News

CytoSorbents Awarded $4.4 Million Contract by The U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development

Monmouth Junction, N.J., July 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the Assistant Secretary of Defense for Health Affairs, endorsed by the Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP), has awarded the Company a three-year...

Read More »
CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery
Health, Medical, & Dental Supplies and Equipment

CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J., Oct. 2, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader using its CytoSorb® blood purification technology to treat life-threatening medical and surgical conditions around the world, announces positive surgical outcomes in a recent publication entitled, "CytoSorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of...

Read More »
Company News

First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence

MONMOUTH JUNCTION, N.J., Sept. 16, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that Hannover Medical School in Germany will begin the first clinical study called...

Read More »
Company News

CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter

MONMOUTH JUNCTION, N.J., Aug. 21, 2018 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) a critical care immunotherapy leader specializing in blood purification, announced today that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), has awarded the company a three-year Phase IIB Bridge SBIR (Small Business Innovation...

Read More »

All Topics

COVID-19 Response Suppliers COVID-19 Response:
Can Your Company Help Provide Critical Supplies?

We are using the power of our platform to aid in the mass shortage of critical supplies. If your company can help provide supplies, capabilities, or materials for products such as N-95 Masks and Tyvek SuitsPlease let us know.

COVID-19 Response Suppliers